Abstract library

736 results for "secondary primary colorectal adenocarcinomas".
#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Student Tobias Stemann Lau
#1466 Delays in Diagnosing Neuroendocrine Tumours by Secondary Care Specialities
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to be a diagnostic challenge, many patients presenting with metastatic disease to a number of specialities in secondary care
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Benny A, Ng S, Reid K, Williams M, ...
#643 Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Professor Young Suk Park
Authors: Park Y S, Ahn H K, Lee J, Choi J Y, ...
Keywords: Pazopanib, GEP-NETs
#1602 Systematic Review of Resecting Primary Tumor in MNETs Patients with Unresectable Liver Metastases
Introduction: Treatment for midgut neuroendocrine tumors (MNETS) with unresectable liver metastasis has long been a controversial issue.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Jingfei Guo
Authors: Guo J, Bi X, Zhou J, Li Z, ...
#821 Incidence of Secondary Neoplasia in Patients with Neuroendocrine Tumor: An Analysis of the SwissNET Database
Introduction: NET are believed to be associated with an increased risk for secondary neoplasia. Previous studies suggest incidence rates between 7% and 46%.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: nnika Blank
Authors: Blank A, Iff S, Stettler C, ...
#635 Neuroendocrine Tumors of the Gastrointestinal Tract with Second Primary Malignancy
Introduction: Neuroendocrine tumors of the gastrointestinal tract (NETs of GIT) are rare neoplasms frequently associated with synchronous or metachronous second primary malignancy (SPM). This phenomenon can be a result of an increasing incidence of NETs in patients who are examined for another primary malignancy. However, other theories suppose genetic predispositions or growth impact of different neuroendocrine peptides produced by NET.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MUDr., PhD. Katarina Machalekova
Authors: Machalekova K, Kajo K, Kajo M, ...
#906 Secondary Hormonal Syndromes in Patients with Sporadic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) are characterized by secretion of peptide hormones that may cause distinct syndromes. Although most patients with hormonal secretion are diagnosed upon primary diagnosis, a significant proportion of pancreatic NET patients develop secondary hormonal production later on in the disease.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Joakim Crona
Authors: Crona J, Eriksson B, Welin S, ...
#437 mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and their Metastases
Introduction: The mammalian target of rapamycin (mTOR), an important regulator of cell proliferation and invasion, is activated in pancreatic neuroendocrine tumors (PNETs). Information on detailed expression of mTOR in locally advanced or metastatic PNET is poorly described.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Vera Delektorskaya
Authors: Kozlov N, Pavlovskaya A, ...
#558 MANECs Among Colorectal Signet Ring Cell Carcinomas
Introduction: The mixed adenoneuroendocrine carcinomas (MANEC, WHO 2010) are neoplasms with heterogeneous morphology, whose mixed nature may be difficult to recognize.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Gratiana Hermann
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...